CRISPR-SONIC: targeted somatic oncogene knock-in enables rapid in vivo cancer modeling.
Haiwei MouDeniz M OzataJordan L SmithAnkur SheelSuet-Yan KwanSoren HoughAlper KucukuralZachary KennedyYueying CaoWen XuePublished in: Genome medicine (2019)
CRISPR/Cas9 has revolutionized cancer mouse models. Although loss-of-function genetics by CRISPR/Cas9 is well-established, generating gain-of-function alleles in somatic cancer models is still challenging because of the low efficiency of gene knock-in. Here we developed CRISPR-based Somatic Oncogene kNock-In for Cancer Modeling (CRISPR-SONIC), a method for rapid in vivo cancer modeling using homology-independent repair to integrate oncogenes at a targeted genomic locus. Using a dual guide RNA strategy, we integrated a plasmid donor in the 3'-UTR of mouse β-actin, allowing co-expression of reporter genes or oncogenes from the β-actin promoter. We showed that knock-in of oncogenic Ras and loss of p53 efficiently induced intrahepatic cholangiocarcinoma in mice. Further, our strategy can generate bioluminescent liver cancer to facilitate tumor imaging. This method simplifies in vivo gain-of-function genetics by facilitating targeted integration of oncogenes.
Keyphrases
- crispr cas
- genome editing
- papillary thyroid
- genome wide
- squamous cell
- copy number
- gene expression
- dna methylation
- escherichia coli
- type diabetes
- cancer therapy
- transcription factor
- childhood cancer
- drug delivery
- lymph node metastasis
- mass spectrometry
- metabolic syndrome
- young adults
- photodynamic therapy
- insulin resistance
- high fat diet induced
- genome wide identification
- loop mediated isothermal amplification